Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)

Peter Rossing; Justus G. Garweg; Stefan D. Anker; Takeshi Osonoi; Bertram Pitt; Sylvia E. Rosas; Luis Miguel Ruilope; Dalong Zhu; Meike Brinker; David Finis; Sergio Leal; Thomas Schmelter; George Bakris

doi:10.1111/dom.14915

Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)

Peter Rossing^*, Justus G. Garweg, Stefan D. Anker, Takeshi Osonoi, Bertram Pitt, Sylvia E. Rosas, Luis Miguel Ruilope, Dalong Zhu, Meike Brinker, David Finis, Sergio Leal, Thomas Schmelter, George Bakris

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Letter › Forskning › peer review

12 Citationer (Scopus)

13 Downloads (Pure)

Originalsprog	Engelsk
Tidsskrift	Diabetes, Obesity and Metabolism
Vol/bind	25
Udgave nummer	3
Sider (fra-til)	894-898
Antal sider	5
ISSN	1462-8902
DOI	https://doi.org/10.1111/dom.14915
Status	Udgivet - 2023

Bibliografisk note

Funding Information:
The authors would like to thank the patients, their families and all investigators involved in this study. Medical writing support, including assisting authors with the development of the initial draft and incorporation of comments, was provided by R. Wright, and editorial support, including referencing, figure preparation, formatting, proofreading and submission, was provided by Ian Norton, PhD, all of Scion, London, supported by Bayer AG according to Good Publication Practice guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460). These data have been previously presented in part at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022) and the 22nd EURETINA Congress (1–4 September 2022). This work was supported by Bayer AG, who funded the ReFineDR and DeFineDR studies and combined analysis.

Funding Information:
This work was funded by Bayer AG, Wuppertal, Germany.

Adgang til dokumentet

10.1111/dom.14915Licens: CC BY-NC-ND

FulltextForlagets udgivne version, 729 KBLicens: CC BY-NC-ND

Citationsformater

Rossing, P., Garweg, J. G., Anker, S. D., Osonoi, T., Pitt, B., Rosas, S. E., Ruilope, L. M., Zhu, D., Brinker, M., Finis, D., Leal, S., Schmelter, T., & Bakris, G. (2023). Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR). Diabetes, Obesity and Metabolism, 25(3), 894-898. https://doi.org/10.1111/dom.14915

Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy : Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR). / Rossing, Peter; Garweg, Justus G.; Anker, Stefan D.; Osonoi, Takeshi; Pitt, Bertram; Rosas, Sylvia E.; Ruilope, Luis Miguel; Zhu, Dalong; Brinker, Meike; Finis, David; Leal, Sergio; Schmelter, Thomas; Bakris, George.

I: Diabetes, Obesity and Metabolism, Bind 25, Nr. 3, 2023, s. 894-898.

Publikation: Bidrag til tidsskrift › Letter › Forskning › peer review

Rossing, P, Garweg, JG, Anker, SD, Osonoi, T, Pitt, B, Rosas, SE, Ruilope, LM, Zhu, D, Brinker, M, Finis, D, Leal, S, Schmelter, T & Bakris, G 2023, 'Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)', Diabetes, Obesity and Metabolism, bind 25, nr. 3, s. 894-898. https://doi.org/10.1111/dom.14915

Rossing P, Garweg JG, Anker SD, Osonoi T, Pitt B, Rosas SE et al. Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR). Diabetes, Obesity and Metabolism. 2023;25(3):894-898. https://doi.org/10.1111/dom.14915

Rossing, Peter ; Garweg, Justus G. ; Anker, Stefan D. ; Osonoi, Takeshi ; Pitt, Bertram ; Rosas, Sylvia E. ; Ruilope, Luis Miguel ; Zhu, Dalong ; Brinker, Meike ; Finis, David ; Leal, Sergio ; Schmelter, Thomas ; Bakris, George. / Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy : Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR). I: Diabetes, Obesity and Metabolism. 2023 ; Bind 25, Nr. 3. s. 894-898.

@article{dfe6e8f72f1a4ecf9d0d35fbff0c8f78,

title = "Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)",

keywords = "diabetic retinopathy, phase III study, randomized trial, type 2 diabetes",

author = "Peter Rossing and Garweg, {Justus G.} and Anker, {Stefan D.} and Takeshi Osonoi and Bertram Pitt and Rosas, {Sylvia E.} and Ruilope, {Luis Miguel} and Dalong Zhu and Meike Brinker and David Finis and Sergio Leal and Thomas Schmelter and George Bakris",

note = "Funding Information: The authors would like to thank the patients, their families and all investigators involved in this study. Medical writing support, including assisting authors with the development of the initial draft and incorporation of comments, was provided by R. Wright, and editorial support, including referencing, figure preparation, formatting, proofreading and submission, was provided by Ian Norton, PhD, all of Scion, London, supported by Bayer AG according to Good Publication Practice guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460). These data have been previously presented in part at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022) and the 22nd EURETINA Congress (1–4 September 2022). This work was supported by Bayer AG, who funded the ReFineDR and DeFineDR studies and combined analysis. Funding Information: This work was funded by Bayer AG, Wuppertal, Germany. ",

year = "2023",

doi = "10.1111/dom.14915",

language = "English",

volume = "25",

pages = "894--898",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy

T2 - Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)

AU - Rossing, Peter

AU - Garweg, Justus G.

AU - Anker, Stefan D.

AU - Osonoi, Takeshi

AU - Pitt, Bertram

AU - Rosas, Sylvia E.

AU - Ruilope, Luis Miguel

AU - Zhu, Dalong

AU - Brinker, Meike

AU - Finis, David

AU - Leal, Sergio

AU - Schmelter, Thomas

AU - Bakris, George

N1 - Funding Information: The authors would like to thank the patients, their families and all investigators involved in this study. Medical writing support, including assisting authors with the development of the initial draft and incorporation of comments, was provided by R. Wright, and editorial support, including referencing, figure preparation, formatting, proofreading and submission, was provided by Ian Norton, PhD, all of Scion, London, supported by Bayer AG according to Good Publication Practice guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460). These data have been previously presented in part at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022) and the 22nd EURETINA Congress (1–4 September 2022). This work was supported by Bayer AG, who funded the ReFineDR and DeFineDR studies and combined analysis. Funding Information: This work was funded by Bayer AG, Wuppertal, Germany.

PY - 2023

Y1 - 2023

KW - diabetic retinopathy

KW - phase III study

KW - randomized trial

KW - type 2 diabetes

U2 - 10.1111/dom.14915

DO - 10.1111/dom.14915

M3 - Letter

C2 - 36331803

AN - SCOPUS:85142871509

VL - 25

SP - 894

EP - 898

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 3

ER -